Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

High dose methotrexate therapy ?The role of the clinical pharmacist?

2nd International Summit on Clinical Pharmacy

Osama M Al-Quteimat

ScientificTracks Abstracts: Clinic Pharmacol Biopharm

DOI: 10.4172/2167-065X.S1.006

Abstract
Methotrexate (MTX) is an antifolate cytotoxic medication used to treat certain types of cancer and at lower doses for rheumatic diseases. MTX has many serious adverse effects, such as myelosuppression, hepatic, renal and pulmonary disorders. For safe and effective use of high dose methotrexate (HDMTX) certain precautions should be followed. We present this case study with short review to briefly summarize the important practical issues related to HDMTX therapy. Case: The case concerns a 21-year-old male patient with osteosarcoma of the right tibia, admitted to the oncology department to receive chemotherapy in the form of 12 g/m2 high-dose methotrexate with leucovorin rescue. Patient is receiving other interacting medications. Clinical pharmacist has a crucial role in optimizing HD-MTX therapy and to prevent potential toxicies. Conclusion: MTX has many serious and sometimes life-threatening side effects that can be avoided by following special precautions during HDMTX administration and post-treatment management guidelines. Close monitoring, adequate hydration and avoidance of interacting drugs are general principles applied to prevent HDMTX toxicity that are common to all regimens.
Biography
Osama M. Al-Quteimat has completed his Master degree in clinical pharmacy at the age of 26 years from University of Jordan. He is a board-certified oncology pharmacist working as clinical pharmacist in King Abdullah Medical City, a leading healthcare institution providing high-quality quaternary healthcare, education and research in Saudi Arabia-Makkah. He has published many papers in the field of clinical pharmacy in reputed journals.
Top